|
|
||||||||
and Free
Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains
1 Mayo Clinic, 200 First St. SW, Rochester, MN 55905.
2 The Binding Site Ltd and The Medical School, University of Birmingham, Birmingham B15 2TT, England.
aAddress correspondence to this author at: Mayo Clinic, Hilton Bldg., Room 920, 200 First St. SW, Rochester, MN 55905. Fax 507-266-4088; e-mail katzmann{at}mayo.edu.
Background: The detection of monoclonal free light chains (FLCs) is an important diagnostic aid for a variety of monoclonal gammopathies and is especially important in light-chain diseases, such as light-chain myeloma, primary systemic amyloidosis, and light-chain-deposition disease. These diseases are more prevalent in the elderly, and assays to detect and quantify abnormal amounts of FLCs require reference intervals that include elderly donors.
Methods: We used an automated immunoassay for FLCs and sera from a population 2190 years of age. We used the calculated reference and diagnostic intervals to compare FLC results with those obtained by immunofixation (IFE) to detect low concentrations of monoclonal
and
FLCs in the sera of patients with monoclonal gammopathies.
Results: Serum
and
FLCs increased with population age, with an apparent change for those >80 years. This trend was lost when the FLC concentration was normalized to cystatin C concentration. The ratio of
FLC to
FLC (FLC K/L) did not exhibit an age-dependent trend. The diagnostic interval for FLC K/L was 0.261.65. The 95% reference interval for
FLC was 3.319.4 mg/L, and that for
FLC was 5.726.3 mg/L. Detection and quantification of monoclonal FLCs by nephelometry were more sensitive than IFE in serum samples from patients with primary systemic amyloidosis and light-chain-deposition disease.
Conclusions: Reference and diagnostic intervals for serum FLCs have been developed for use with a new, automated immunoassay that makes the detection and quantification of monoclonal FLCs easier and more sensitive than with current methods. The serum FLC assay complements IFE and allows quantification of FLCs in light-chain-disease patients who have no detectable serum or urine M-spike.
The following articles in journals at HighWire Press have cited this article:
![]() |
A. D. Wechalekar, H. J. Lachmann, H. J. B. Goodman, A. Bradwell, P. N. Hawkins, and J. D. Gillmore AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome Blood, November 15, 2008; 112(10): 4009 - 4016. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Katzmann and A. Dispenzieri Screening Algorithms for Monoclonal Gammopathies Clin. Chem., November 1, 2008; 54(11): 1753 - 1755. [Full Text] [PDF] |
||||
![]() |
C. A. Hutchison, S. Harding, P. Hewins, G. P. Mead, J. Townsend, A. R. Bradwell, and P. Cockwell Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1684 - 1690. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Piehler, N. Gulbrandsen, P. Kierulf, and P. Urdal Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population Clin. Chem., November 1, 2008; 54(11): 1823 - 1830. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dispenzieri, L. Zhang, J. A. Katzmann, M. Snyder, E. Blood, R. DeGoey, K. Henderson, R. A. Kyle, M. M. Oken, A. R. Bradwell, et al. Appraisal of immunoglobulin free light chain as a marker of response Blood, May 15, 2008; 111(10): 4908 - 4915. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Bochtler, U. Hegenbart, C. Heiss, A. Benner, F. Cremer, M. Volkmann, J. Ludwig, J. B. Perz, A. D. Ho, H. Goldschmidt, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis Haematologica, March 1, 2008; 93(3): 459 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dispenzieri, R. A. Kyle, J. A. Katzmann, T. M. Therneau, D. Larson, J. Benson, R. J. Clark, L. J. Melton III, M. A. Gertz, S. K. Kumar, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma Blood, January 15, 2008; 111(2): 785 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Daval, A. Tridon, N. Mazeron, J.-M. Ristori, and B. Evrard Risk of Antigen Excess in Serum Free Light Chain Measurements Clin. Chem., November 1, 2007; 53(11): 1985 - 1986. [Full Text] [PDF] |
||||
![]() |
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica, October 1, 2007; 92(10): 1351 - 1358. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, O. Hermine, C. Recher, B. Asli, B. Lioure, B. Royer, et al. High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis N. Engl. J. Med., September 13, 2007; 357(11): 1083 - 1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-X. Wang and P. W. Sanders Immunoglobulin Light Chains Generate Hydrogen Peroxide J. Am. Soc. Nephrol., April 1, 2007; 18(4): 1239 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Hutchison, P. Cockwell, S. Reid, K. Chandler, G. P. Mead, J. Harrison, J. Hattersley, N. D. Evans, M. J. Chappell, M. Cook, et al. Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and In Vivo Studies J. Am. Soc. Nephrol., March 1, 2007; 18(3): 886 - 895. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Mosbauer, F. Ayuk, H. Schieder, M. Lioznov, A. R. Zander, and N. Kroger Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation Haematologica, February 1, 2007; 92(2): 275 - 276. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Wechalekar, H. J. B. Goodman, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis Blood, January 15, 2007; 109(2): 457 - 464. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ramasamy Serum Free Light Chain Analysis in B-cell Dyscrasias Ann. Clin. Lab. Sci., January 1, 2007; 37(3): 291 - 294. [Full Text] [PDF] |
||||
![]() |
J-E Gottenberg, F Aucouturier, J Goetz, C Sordet, I Jahn, M Busson, J-M Cayuela, J Sibilia, and X Mariette Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome Ann Rheum Dis, January 1, 2007; 66(1): 23 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Blade Monoclonal Gammopathy of Undetermined Significance N. Engl. J. Med., December 28, 2006; 355(26): 2765 - 2770. [Full Text] [PDF] |
||||
![]() |
V. Sanchorawala Light-Chain (AL) Amyloidosis: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1331 - 1341. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Dingli, R. A. Kyle, S. V. Rajkumar, G. S. Nowakowski, D. R. Larson, J. P. Bida, M. A. Gertz, T. M. Therneau, L. J. Melton III, A. Dispenzieri, et al. Immunoglobulin free light chains and solitary plasmacytoma of bone Blood, September 15, 2006; 108(6): 1979 - 1983. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Katzmann Serum Free Light Chain Specificity and Sensitivity: A Reality Check Clin. Chem., September 1, 2006; 52(9): 1638 - 1639. [Full Text] [PDF] |
||||
![]() |
P. G. Hill, J. M. Forsyth, B. Rai, and S. Mayne Serum Free Light Chains: An Alternative to the Urine Bence Jones Proteins Screening Test for Monoclonal Gammopathies Clin. Chem., September 1, 2006; 52(9): 1743 - 1748. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Palladini, F. Lavatelli, P. Russo, S. Perlini, V. Perfetti, T. Bosoni, L. Obici, A. R. Bradwell, G. M. D'Eril, R. Fogari, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL Blood, May 15, 2006; 107(10): 3854 - 3858. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Dispenzieri, M. Q. Lacy, J. A. Katzmann, S. V. Rajkumar, R. S. Abraham, S. R. Hayman, S. K. Kumar, R. Clark, R. A. Kyle, M. R. Litzow, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood, April 15, 2006; 107(8): 3378 - 3383. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Abadie and D. D. Bankson Assessment of serum free light chain assays for plasma cell disorder screening in a veterans affairs population. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 157 - 162. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. Jaskowski, C. M. Litwin, and H. R. Hill Detection of {kappa} and {lambda} Light Chain Monoclonal Proteins in Human Serum: Automated Immunoassay versus Immunofixation Electrophoresis Clin. Vaccine Immunol., February 1, 2006; 13(2): 277 - 280. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Donato, A. M. Feasel, D. M. Weber, V. G. Prieto, S. A. Giralt, R. E. Champlin, and M. Duvic Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation Blood, January 15, 2006; 107(2): 463 - 466. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Nowrousian, D. Brandhorst, C. Sammet, M. Kellert, R. Daniels, P. Schuett, M. Poser, S. Mueller, P. Ebeling, A. Welt, et al. Serum Free Light Chain Analysis and Urine Immunofixation Electrophoresis in Patients with Multiple Myeloma Clin. Cancer Res., December 15, 2005; 11(24): 8706 - 8714. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Q. Lacy, W. J. Hogan, M. A. Gertz, A. Dispenzieri, S. V. Rajkumar, S. Hayman, S. Kumar, M. R. Litzow, and A. L. Schroeter Successful Treatment of Scleromyxedema With Autologous Peripheral Blood Stem Cell Transplantation Arch Dermatol, October 1, 2005; 141(10): 1277 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Falk Diagnosis and Management of the Cardiac Amyloidoses Circulation, September 27, 2005; 112(13): 2047 - 2060. [Full Text] [PDF] |
||||
![]() |
J. A. Viedma, N. Garrigos, and S. Morales Comparison of the Sensitivity of 2 Automated Immunoassays with Immunofixation Electrophoresis for Detecting Urine Bence Jones Proteins Clin. Chem., August 1, 2005; 51(8): 1505 - 1507. [Full Text] [PDF] |
||||
![]() |
S. V. Rajkumar, R. A. Kyle, T. M. Therneau, L. J. Melton III, A. R. Bradwell, R. J. Clark, D. R. Larson, M. F. Plevak, A. Dispenzieri, and J. A. Katzmann Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance Blood, August 1, 2005; 106(3): 812 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Bradwell Serum Free Light Chain Measurements Move to Center Stage Clin. Chem., May 1, 2005; 51(5): 805 - 807. [Full Text] [PDF] |
||||
![]() |
J. A. Katzmann, R. S. Abraham, A. Dispenzieri, J. A. Lust, and R. A. Kyle Diagnostic Performance of Quantitative {kappa} and {lambda} Free Light Chain Assays in Clinical Practice Clin. Chem., May 1, 2005; 51(5): 878 - 881. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Rajkumar MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management Hematology, January 1, 2005; 2005(1): 340 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Tate, D. Gill, R. Cobcroft, and P. E. Hickman Practical Considerations for the Measurement of Free Light Chains in Serum Clin. Chem., August 1, 2003; 49(8): 1252 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Abraham, M. C. Charlesworth, B. A.L. Owen, L. M. Benson, J. A. Katzmann, C. B. Reeder, and R. A. Kyle Trimolecular Complexes of {lambda} Light Chain Dimers in Serum of a Patient with Multiple Myeloma Clin. Chem., October 1, 2002; 48(10): 1805 - 1811. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |